• Home
  • Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium.

Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium.

Author List
K.J. Curran, V.A. Fabrizio, A. Mauguen, J.J. Boelens, C. Baggott, S. Prabhu, H. Placenta, C.L. Phillips, J. Rossoff, H. Stefanski, J. Talano, A. Moskop, S.P. Margossian, M.R. Verneris, G. Myers, N.A. Karras, P.A. Brown, M. Qayed, M. Hermiston, P. Satwani, C. Krupski, A. Keating, R. Wilcox, C.A. Rabik, V. Chinnabhandar, M. Kunicki, A. Goksenin, C. Mackall, T.W. Laetsch, L.M. Schultz
Publication
Cytotherapy
Publication ID (Profile URL)
https://researcherprofiles.org/profile/200871468
Publication Year
2021
Publication Title
K.J. Curran, V.A. Fabrizio, A. Mauguen, J.J. Boelens, C. Baggott, S. Prabhu, H. Placenta, C.L. Phillips, J. Rossoff, H. Stefanski, J. Talano, A. Moskop, S.P. Margossian, M.R. Verneris, G. Myers, N.A. Karras, P.A. Brown, M. Qayed, M. Hermiston, P. Satwani, C. Krupski, A. Keating, R. Wilcox, C.A. Rabik, V. Chinnabhandar, M. Kunicki, A. Goksenin, C. Mackall, T.W. Laetsch, L.M. Schultz. Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium. Cytotherapy. 2021 May 1; 23(5):s27.